Industry criticises “politicisation” of drug reimbursement decisions in Australia
This article was originally published in SRA
Executive Summary
Pharmaceutical companies are warning the Australian government about the potential consequences of a recent policy change that they believe is resulting in the government delaying indefinitely the final decision on whether drugs should be reimbursed under the country's state-funded pharmaceutical benefits scheme. Jamie Nicholson, spokesperson for the industry association Medicines Australia, said that he was "aware of at least a couple of companies who have hit the pause button in terms of bringing new medicines to Australia until the policy outlook becomes clearer"1.
You may also be interested in...
US FDA head Hamburg declares no one can inspect world on its own
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
FDA's Hamburg declares no one can "inspect world on its own" for poor quality medicines
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Pharma and MSF agree on competition for cheap vaccines, but differ on pricing
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.